Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma.

INTRODUCTION: Anthracycline chemotherapy contributes to improved outcomes in Ewing sarcoma; however, the most feared complication is cardiotoxicity. Echocardiograms were routinely used to monitor cardiac function after anthracycline treatment. Nevertheless, indices chosen to assess cardiac toxicity vary significantly among different centers, and no uniform protocol has been accepted as ideal. METHODS: This retrospective study included children with Ewing sarcoma treated at Children's Cancer Hospital Egypt over 4years. All echocardiograms and related clinical assessments were reviewed. RESULTS: In total, 149 patients (median age 11years; range 1-18years) were included. Although all patients had a reduced ejection fraction compared with their baseline echocardiogram, only 39 patients developed cardiotoxicity (26%): 43% acute-onset, 36% chronic early-onset, and 21% chronic late-onset. There were no statistically significant association between the frequency of myocardial dysfunction and risk factors, including age, sex, follow-up duration, cumulative doxorubicin dose, and mediastinal irradiation. Over one-third (39%) of the patients with cardiac toxicity regained normal cardiac parameters, whereas seven patients died of acute cardiac toxicity. CONCLUSION: The routine use of echocardiography to screen for anthracycline-induced cardiac toxicity before and during chemotherapy identified myocardial dysfunction. Early medical intervention can improve cardiac parameters. Improved screening techniques with better sensitivity and predictability are needed.

A preliminary report on the impact of ¹8F-FDG PET/CT in the management of paediatric head and neck cancer.

INTRODUCTION: Paediatric head and neck malignancy accounts for 5% of all paediatric cancers. The choice of treatment and prediction of prognosis depend on the histological type of tumour, initial staging, evaluating treatment response and detection of early recurrence. Conventional imaging modalities have many limitations. Positron emission tomography/computed tomography (PET/CT) is more accurate; however, so far, the literature lacks reports of large groups of paediatric patients. AIM: To report the role of PET/CT in factors affecting the choice of treatment at the newly established Children Cancer Hospital in Cairo, Egypt, which is one of the busiest dedicated paediatric oncology centres in the world. All findings were proven by histopathology, radiology and by clinical follow-up. PATIENT POPULATION: Thirty-six paediatric patients (30 boys and six girls) with various histologically proven head and neck cancers were included in this study. Their age ranged from 2 to 17 years. High-resolution diagnostic CT and/or MRI of the head and neck, and in relevant cases also of the chest and the abdomen, were performed in all patients at a mean interval of 1.6 weeks (range, 1-3 months) before the PET/CT study. Results of PET/CT were compared with the findings of these conventional imaging modalities. RESULTS: The sensitivity, specificity, accuracy, positive and negative predictive values of PET/CT against the conventional imaging were as follows: sensitivity 100 and, 53%, specificity 89.5 and 47%, accuracy 94.5 and 50%, positive predictive value 89.5 and 47% and negative predictive value 100 and 53% respectively. PET/CT changed patient management in 50% of the cases. CONCLUSION: PET/CT in paediatric head and neck carcinoma is more accurate than conventional imaging. Therefore, it also has a significant impact on further patient management. We recommend that it should be the first imaging modality for all purposes in initial staging, evaluating treatment response and follow-up in paediatric head and neck carcinoma.